Data from the 739 patient SIRFLOX and FOXFIRE Global studies indicate:
- OS was significantly improved by the addition of SIRT with liver-directed SIR-Spheres® Y-90 resin microspheres to first-line mFOLFOX6 chemotherapy (± bevacizumab) in mCRC patients with a Right-Sided Primary (RSP) tumour (median 22.0 vs. 17.1 months, with vs. without SIRT respectively; HR: 0.64 [95% CI: 0.46–0.89] p=0.008), which translates into a 36% reduction in the risk of death at any time compared to patients receiving chemotherapy alone.
- No significant improvement in survival was seen from the addition of SIRT to first-line mFOLFOX6 chemotherapy for patients with Left-Sided Primary (LSP) tumours (median 24.6 vs. 26.6 months, with vs. without SIRT respectively; HR: 1.12 [95% CI: 0.92–1.37] p=0.264).
bev*: bevacizumab (bevacizumab allowed at investigator’s discretion, per institutional practice)
Gibbs P et al. Clin Col Cancer 2018 Jun 12 ePub: doi: 10.1016/j.clcc.2018.06.001.